These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 31488712)

  • 1. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities.
    Li J; Wang PY; Long NA; Zhuang J; Springer DA; Zou J; Lin Y; Bleck CKE; Park JH; Kang JG; Hwang PM
    Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19626-19634. PubMed ID: 31488712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
    Cunha-Oliveira T; Ferreira LL; Coelho AR; Deus CM; Oliveira PJ
    Toxicol Appl Pharmacol; 2018 Jun; 348():1-13. PubMed ID: 29653124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise-induced mitochondrial p53 repairs mtDNA mutations in mutator mice.
    Safdar A; Khrapko K; Flynn JM; Saleem A; De Lisio M; Johnston AP; Kratysberg Y; Samjoo IA; Kitaoka Y; Ogborn DI; Little JP; Raha S; Parise G; Akhtar M; Hettinga BP; Rowe GC; Arany Z; Prolla TA; Tarnopolsky MA
    Skelet Muscle; 2016; 6():7. PubMed ID: 26834962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways.
    Ma J; Wang Y; Zheng D; Wei M; Xu H; Peng T
    Cardiovasc Res; 2013 Jan; 97(1):77-87. PubMed ID: 23027656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for p53 as guardian of the cardiomyocyte mitochondrial genome following acute adriamycin treatment.
    Nithipongvanitch R; Ittarat W; Velez JM; Zhao R; St Clair DK; Oberley TD
    J Histochem Cytochem; 2007 Jun; 55(6):629-39. PubMed ID: 17312011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered mitochondrial epigenetics associated with subchronic doxorubicin cardiotoxicity.
    Ferreira A; Cunha-Oliveira T; Simões RF; Carvalho FS; Burgeiro A; Nordgren K; Wallace KB; Oliveira PJ
    Toxicology; 2017 Sep; 390():63-73. PubMed ID: 28865727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway.
    Zhu W; Soonpaa MH; Chen H; Shen W; Payne RM; Liechty EA; Caldwell RL; Shou W; Field LJ
    Circulation; 2009 Jan; 119(1):99-106. PubMed ID: 19103993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 improves aerobic exercise capacity and augments skeletal muscle mitochondrial DNA content.
    Park JY; Wang PY; Matsumoto T; Sung HJ; Ma W; Choi JW; Anderson SA; Leary SC; Balaban RS; Kang JG; Hwang PM
    Circ Res; 2009 Sep; 105(7):705-12, 11 p following 712. PubMed ID: 19696408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity.
    Yoshida M; Shiojima I; Ikeda H; Komuro I
    J Mol Cell Cardiol; 2009 Nov; 47(5):698-705. PubMed ID: 19660469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Protect Cardiomyocytes from Doxorubicin-Induced Cardiomyopathy by Upregulating Survivin Expression via the miR-199a-3p-Akt-Sp1/p53 Signaling Pathway.
    Lee JY; Chung J; Byun Y; Kim KH; An SH; Kwon K
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Abl1 tyrosine kinase is a key player in doxorubicin-induced cardiomyopathy and its p53/p73 cell death mediated signaling differs in atrial and ventricular cardiomyocytes.
    Borlak J; Ciribilli Y; Bisio A; Selvaraj S; Inga A; Oh JH; Spanel R
    J Transl Med; 2024 Sep; 22(1):845. PubMed ID: 39285385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triptolide induces p53-dependent cardiotoxicity through mitochondrial membrane permeabilization in cardiomyocytes.
    Xi Y; Wang W; Wang L; Pan J; Cheng Y; Shen F; Huang Z
    Toxicol Appl Pharmacol; 2018 Sep; 355():269-285. PubMed ID: 30009776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice.
    Shizukuda Y; Matoba S; Mian OY; Nguyen T; Hwang PM
    Mol Cell Biochem; 2005 May; 273(1-2):25-32. PubMed ID: 16013437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin-induced p53 interferes with mitophagy in cardiac fibroblasts.
    Mancilla TR; Davis LR; Aune GJ
    PLoS One; 2020; 15(9):e0238856. PubMed ID: 32960902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qishen Granule Protects against Doxorubicin-Induced Cardiotoxicity by Coordinating MDM2-p53-Mediated Mitophagy and Mitochondrial Biogenesis.
    Li W; Zhang Y; Wang X; Cao J; Qian W; Ling G; Tan N; Jiang J; Sun Q; Li C; Wang W; Wang Y
    Oxid Med Cell Longev; 2022; 2022():4344677. PubMed ID: 36120600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice.
    Pillai VB; Bindu S; Sharp W; Fang YH; Kim G; Gupta M; Samant S; Gupta MP
    Am J Physiol Heart Circ Physiol; 2016 Apr; 310(8):H962-72. PubMed ID: 26873966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis.
    Lebedeva MA; Eaton JS; Shadel GS
    Biochim Biophys Acta; 2009 May; 1787(5):328-34. PubMed ID: 19413947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-specific regulation of p53 by PKM2 is redox dependent and provides a therapeutic target for anthracycline-induced cardiotoxicity.
    Saleme B; Gurtu V; Zhang Y; Kinnaird A; Boukouris AE; Gopal K; Ussher JR; Sutendra G
    Sci Transl Med; 2019 Feb; 11(478):. PubMed ID: 30728290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-146a attenuates apoptosis and modulates autophagy by targeting TAF9b/P53 pathway in doxorubicin-induced cardiotoxicity.
    Pan JA; Tang Y; Yu JY; Zhang H; Zhang JF; Wang CQ; Gu J
    Cell Death Dis; 2019 Sep; 10(9):668. PubMed ID: 31511497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin induces cardiotoxicity in a pluripotent stem cell model of aggressive B cell lymphoma cancer patients.
    Haupt LP; Rebs S; Maurer W; Hübscher D; Tiburcy M; Pabel S; Maus A; Köhne S; Tappu R; Haas J; Li Y; Sasse A; Santos CCX; Dressel R; Wojnowski L; Bunt G; Möbius W; Shah AM; Meder B; Wollnik B; Sossalla S; Hasenfuss G; Streckfuss-Bömeke K
    Basic Res Cardiol; 2022 Mar; 117(1):13. PubMed ID: 35260914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.